Leica Biosystems acquires Kreatech Diagnostics
Leica Biosystems announced that it has acquired Kreatech Diagnostics, a privately-held provider of DNA fluorescent in-situ hybridization (FISH) probes and target labeling reagents for microarrays.
“We are very pleased with the acquisition of Kreatech, its extensive portfolio and development expertise. This will allow Leica Biosystems to better serve our cytogenetics and anatomic pathology customers. It will also enable us to actively support the future development of personalized medicine by research and drug development companies” said Matthias G. Weber, MD, President of Leica Biosystems. “By standardizing and supporting the interpretation of results with our Aperio ePathologytm imaging solutions, we will provide our customers with the ability to effectively and efficiently manage ever more complex diagnostic requirements.”
Kreatech will join Leica Biosystems’ Advanced Staining Business Unit based in Newcastle-upon-Tyne, UK. The combined business will develop targeted biomarker menus for Leica’s instrument platforms. Leica Biosystems provides the ThermoBrite®, and BOND™ systems that are widely used to label tissue specimens for diagnostic interpretation in cytogenetics and pathology laboratories globally.
Other news from the department business & finance
